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SUMMARY
1. The aim of the present study was to investigate the
effects of vascular tissue levels of L-carnitine and its precur-
sor, c-butyrobetaine (GBB), on the development of endothelial
dysfunction induced by 5 lmol/L lysophosphatidylcholine
(LPC), 10 mmol/L triglycerides (TG) or a high glucose
concentration (44 mmol/L).
2. Changes in vascular tissue levels of L-carnitine and GBB
were induced by administration of L-carnitine (100 mg/kg),
mildronate (100 mg/kg; an inhibitor of L-carnitine synthesis)
or their combination to male Wistar rats for 2 weeks.
3. Treatment with L-carnitine elevated vascular tissue levels
of L-carnitine, whereas administration of mildronate reduced
L-carnitine levels and increased GBB levels. Experimental
animals that received the combination of both drugs showed
elevated tissue levels of GBB.
4. The results from organ bath experiments demonstrated
that increased GBB levels with preserved L-carnitine content
in vascular tissues attenuated the development of endothelial
dysfunction induced by high glucose. However, changes in
vascular tissue L-carnitine and GBB levels had no impact on
endothelial dysfunction induced by TG or LPC.
5. The results demonstrate that increased levels of GBB
with preserved L-carnitine content in vascular tissue attenuate
the development of endothelial dysfunction induced by high
glucose concentrations.
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INTRODUCTION
L-Carnitine is a molecule that is involved in the energy metabo-
lism of muscle cells and is necessary for long-chain fatty acid
influx into the mitochondria, where b-oxidation takes place. In
mammals, L-carnitine can be obtained through the diet or synthe-
sized in the liver and kidneys from its precursor c-butyrobetaine
(GBB) by GBB dioxygenase.1
Several studies have shown that reduction in the amount of
L-carnitine in cardiac tissues is a promising approach to protect
the heart against ischaemia–reperfusion injury in healthy, as well
as diabetic, rats.2,3 It has been demonstrated that reductions in
tissue levels of L-carnitine attenuate the metabolism of fatty
acids4 and simultaneously facilitate glucose metabolism.5 It has
been proposed that this shift of cellular energy metabolism is
responsible for the cardioprotective effects.2 In these studies,
tissue levels of L-carnitine were reduced by the administration of
mildronate, which is an inhibitor of both the synthesis and renal
reabsorption of L-carnitine.6 Increased tissue levels of GBB were
observed along with the reduction in the amount of L-carni-
tine.2,3 c-Butyrobetaine is a substrate for the last step of the syn-
thesis of L-carnitine.1 Moreover, some experimental data indicate
that GBB may have other functions and properties. For example,
it has been shown that GBB itself possesses cardioprotective
activity.7
In previous studies we showed that decreased L-carnitine and
increased GBB levels in vascular tissues induced anti-atheroscle-
rotic effects in an experimental model of atherosclerosis8 and that
marked elevations of GBB in the plasma could attenuate the
development of endothelial dysfunction in an experimental model
of hypertension.9 These findings suggest that changes in vascular
tissue levels of L-carnitine and GBB could induce vasoprotective
effects.
Therefore, the aim of the present study was to investigate
the effects of changing vascular tissue levels of L-carnitine and
GBB on the development of endothelial dysfunction induced
by high concentrations of glucose,10 triglycerides (TG)11 or
lysophosphatidylcholine (LPC).12 Each of the substances used
was chosen because they represent aetiological factors for the
development of endothelial dysfunction in different diseases.
Elevated glucose concentrations are linked to the impairment
of endothelial function in diabetes;13 hypertriglyceridaemia is
involved in the development of endothelial dysfunction in
experimental models of metabolic syndrome;14 and LPC is a
lipid constituent in oxidized low-density lipoproteins, which are
involved in the development of endothelial dysfunction in
atherosclerosis.15 Concentrations of substances that induce
impairment of function of vascular endothelium were chosen
similar or close to those that have been observed in corre-
sponding animal models of the disease.16,17 Alterations in
vascular tissue levels of L-carnitine and GBB were induced by
the administration of L-carnitine, mildronate (an inhibitor of L-
carnitine biosynthesis) or their combination to male Wistar rats
for 2 weeks.
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METHODS
Chemicals
Mildronate dihydrate was obtained from JSC Grindeks (Riga,
Latvia). Ketamine hydrochloride solution (Bioketan) was
obtained from Vetoquinol Biowet (Gorzow Wielkopolski, Poland)
and xylazine hydrochloride solution (Seton) was from Laboratori-
os Calier (Barcelona, Spain). Acetonitrile and methanol were
obtained from Merck (Darmstadt, Germany). L-Carnitine, sodium
chloride, potassium chloride, calcium chloride dihydrate,
magnesium chloride hexahydrate, sodium hydrogencarbonate,
potassium dihydrogenphosphate, glucose, EDTA, L-phenylephrine
hydrochloride, acetylcholine chloride, ammonium acetate,
lysophosphatidylcholine, sodium nitroprusside (SNP), mannitol
and collagenase type IV were purchased from Sigma (Schnell-
dorf, Germany). Intralipid was obtained from Fresenius Kabi
(Bad Homburg, Germany).
Experimental animals
Male Wistar rats (7–8 weeks old), weighing 200–240 g, were
obtained from the Laboratory of Experimental Animals, Riga
Stradins University (Riga, Latvia) and housed under standard
conditions (21–23°C, 12 h light–dark cycle, relative humidity
45%–65%) with unlimited access to standard pelletted rat chow
(R3 diet; Lactamin, Kimstad, Sweden) and water.
The experimental procedures were performed in accordance
with the guidelines of the European Community as well as local
laws and policies, and were approved by the Latvian Animal Pro-
tection Ethics Committee of the Food and Veterinary Service,
Riga, Latvia.
Treatment and experimental protocol
Rats were adapted to the new housing conditions for 1 week
prior to treatment. For each experimental protocol, 24 experi-
mental animals were used. Rats were randomly separated into
four experimental groups. Experimental animals in the first
group received drinking water (control group; n = 6), rats in
the second group received 100 mg/kg per day mildronate dis-
solved in the drinking water (n = 6), rats in the third group
received L-100 mg/kg per day carnitine dissolved in the drink-
ing water (n = 6) and rats in the fourth group received a com-
bination of mildronate and L-carnitine (100 mg/kg per day
each dissolved in the drinking water; n = 6) for 2 weeks. The
dosing of mildronate, L-carnitine and their combination was
confirmed by measuring the consumption of drinking water
every 2 days and adjusting the concentration of supplemented
substances.
Until now, administration of a combination of L-carnitine and
mildronate is the only known way to elevate GBB levels without
decreasing L-carnitine levels.9 The doses of L-carnitine and mildr-
onate in the combination group were chosen based on the results
of a previous study9 in which administration of the same combi-
nation attenuated the development of endothelial dysfunction in
an experimental model of hypertension and simultaneously ele-
vated plasma GBB concentrations. The dose of mildronate used
herein was chosen on the basis of results from previous studies
in which 100 mg/kg mildronate exhibited cardioprotective3 and
vasoprotective8 effects. In the group receiving L-carnitine, the
dose of L-carnitine used was the same as in the combination
group to differentiate the effects of L-carnitine from the effects of
combination drug treatment.
The experimental animals were anaesthetized with an intraperi-
toneal injection of a mixture of 100 mg/kg ketamine and 10 mg/
kg xylazine 24 h after the last administration of the test com-
pounds. After the onset of anaesthesia, the chest was opened and
blood was withdrawn from the right ventricle using a syringe and
then transferred into a test tube containing heparin. Plasma sam-
ples were prepared by centrifugation at 1000 g for 10 min at 4°C.
The plasma samples were stored at 80°C until further analysis.
The thoracic aorta was excised and used to measure tissue
levels of L-carnitine, GBB and mildronate, or for the assessment
of endothelial function in an isolated aortic ring model.
One author (RV) blinded to the identity of the treatment
groups performed all the experimental procedures and analyses.
During the study, two experimental animals were excluded
from the further experiments due to the development of lung can-
cer. In addition, results from one experimental animal were
excluded from analysis due to unexpected technical problems
during organ bath experiments.
Quantification of L-carnitine, GBB and mildronate
The cleaned thoracic aorta was cut into small pieces and incu-
bated in 1 mL Krebs’–Henseleit (K-H) buffer (composition (in
mmol/L): NaCl 118; CaCl2 2.5; MgCl2 1.64; NaHCO3 24.88;
KH2PO4 1.18; glucose 10.0; EDTA 0.05), pH 7.4 at 37°C, con-
taining collagenase type IV (2 mg/mL) until absolute diffluence
was achieved. L-Carnitine, GBB and mildronate concentrations in
aortic tissue extracts and plasma samples were determined by
ultra performance liquid chromatography (UPLC)–tandem mass
spectrometry (MS/MS) in positive ion electrospray mode, as
described previously.18 Briefly, the UPLC was performed using
an Acquity UPLC system (Waters, Milford, MA, USA) with a
Waters Acquity HILIC BEH 1.7 lm 2.1 9 100 mm column; the
injection volume was 5 lL. Chromatographic separation was per-
formed in 10 mmol/L ammonium acetate (pH = 4; Solution A)
and acetonitrile (Solution B) gradient (0 min 75% Solution B;
2.5 min 55% Solution B; 4 min 50% Solution B) at a flow rate
of 0.25 mL/min. The MS/MS analysis was performed on a Mi-
cromass Quattro Micro tandem mass spectrometer (Waters). Data
were acquired and processed using MassLynx 4.1. software with
a QuanLynx 4.1 module (Waters).
Organ chamber experiments
Endothelial function was examined in aortic rings in an organ
bath as described previously.9 The excised thoracic aorta was
immersed in ice-cold K-H buffer and cleaned of fatty and con-
nective tissues. The aorta was cut into rings that were 3–4 mm in
length. The aortic rings were mounted between two stainless steel
hooks in oxygenated K-H buffer solution (pH 7.4, 37°C). The
passive tension was fixed at 20 mN. After a period of equilibra-
tion (1 h), maximal contractile function was assessed by applica-
tion of 60 mmol/L KCl. The aortic rings were then precontracted
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to 60%–80% of maximal contraction with phenylephrine and a
cumulative response curve to acetylcholine (ACh; 109 to
105 mol/L) was constructed. After assessment of endothelial
function, the aortic rings were incubated in K-H buffer containing
agents that impair endothelial function. All the experimental pro-
cedures and agents used to induce endothelial dysfunction in the
present study have been described previously.10–12 In the first
experimental protocol, endothelial dysfunction was induced by
incubation of the aortic rings in a solution containing a high
glucose concentration (44 mmol/L) for 3 h. In the second experi-
mental protocol, the function of the vascular endothelium was
impaired by incubation of aortic rings in a solution containing a
high concentration of TG (10 mmol/L) for 30 min. In the third
experimental protocol, endothelial dysfunction was induced by
incubation of aortic rings in a buffer containing 5 lmol/L LPC
for 30 min After incubation in the presence of the various agents,
the aortic rings were precontracted to 60%–80% of maximal con-
traction with phenylephrine and cumulative response curves to
ACh (109 to 105 mol/L) were constructed.
To exclude the osmotic effects of glucose on the function of
the vascular endothelium, aortic rings from control animals were
isolated and endothelial function was assessed before and after
incubation in K-H buffer with 33 mmol/L mannitol. In addition,
to test the effects of incubation of aortic rings with endothelium
dysfunction-inducing agents on vascular smooth muscle function,
endothelium-independent relaxation was assessed using SNP.
The relaxation of aortic rings in the presence of acetylcholine
or SNP was expressed as the percentage of the phenylephrine-
induced constriction and the EC50 for each drug was calculated
for each aortic ring using Prism 3.0 software (GraphPad, San
Diego, CA, USA).
Statistical analysis
Results are expressed as the mean  SEM. The Kolmogorov–
Smirnov test was used to test the distribution of the results
obtained. Because the data were normally distributed, the signifi-
cance of differences between mean values was evaluated using
parametric tests. One-way analysis of variance (ANOVA) followed
by Tukey’s multiple comparison test as a post hoc test was used
to compare the mean amount of L-carnitine, GBB and mildronate
in plasma and aortic extract samples. The same test was used to
compare EC50 values in all four groups before the incubation of
aortic rings with endothelial dysfunction-inducing agents.
Repeated-measures ANOVA followed by Bonferroni’s multiple
comparison test as a post hoc test was used to compare responses
to ACh before and after incubation of aortic rings with endothe-
lial dysfunction-inducing agents. For the comparison of maximal
ACh-induced relaxation (Emax) in the LPC-induced endothelial
dysfunction model, a paired t-test was performed. In addition,
paired t-tests were used to compare mean EC50 values for SNP-
and ACh-induced relaxations before and after incubation of aortic
rings with mannitol. Two-sided P < 0.05 was considered signifi-
cant.
RESULTS
Analysis of aortic tissue extracts revealed that the administration
of mildronate, L-carnitine or their combination induced alterations
in vascular tissue levels of GBB and L-carnitine (Fig. 1). In the
control group, the average L-carnitine aortic tissue content was
560  40 nmol/g protein. Treatment with mildronate decreased
vascular tissue levels of L-carnitine by 52%, but administration of
100 mg/kg L-carnitine for 2 weeks elevated vascular tissue levels
of L-carnitine by 36%. Simultaneous administration of mildronate
and L-carnitine slightly reduced the L-carnitine content in vascular
tissues, but the decrease was not significant.
The average GBB content in vascular tissues of the control
group was 40  2 nmol/g protein (Fig. 1b). Treatment with
mildronate and the combination of mildronate and L-carnitine
resulted in a pronounced increase in GBB levels (3.2- and 3.4-
fold increase, respectively). Analysis of the mildronate content
revealed that the mean amount of mildronate in vascular tissues
in the mildronate-treated group was 410  30 nmol/g protein,
whereas in the combination group it was reduced by > 50%
(190  10 nmol/g protein).
Treatment of experimental animals with mildronate, L-carnitine
or their combination induced changes in plasma GBB and
L-carnitine concentrations similar to those seen in aortic tissue
(Table 1). The only difference was that the administration of the
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Fig. 1 Vascular tissue levels of (a) L-carnitine and (b) c-butyrobetaine
(GBB) after 2 weeks treatment with mildronate, L-carnitine or their
combination. Administration of mildronate decreased L-carnitine levels
in vascular tissues, whereas administration of L-carnitine increased
L-carnitine content. In addition, treatment of rats with mildronate and the
combination of mildronate and L-carnitine increased GBB levels in vascu-
lar tissues. Data are the mean  SEM (n = 5–6 rats). *P < 0.05 com-
pared with the control group; †P < 0.05 compared with the combination
group (one-way ANOVA followed by Tukey’s multiple comparison test as a
post-test; six multiple comparisons).
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higher increase in GBB concentrations than the administration of
mildronate alone (16.1  4.4 vs 6.1  0.9 lmol/L, respectively;
P < 0.05).
The endothelial effects were evaluated in an isolated thoracic
aortic ring model, in which ACh was used to induce endothe-
lium-dependent relaxation. The average EC50 values for ACh ran-
ged between 30 and 52 nmol/L (Fig. 2; Table 2) and agreed with
those from previous studies.11,12 Moreover, there were no signifi-
cant differences in EC50 values for ACh among the experimental
groups before the incubation of aortic rings with the endothelial
dysfunction-inducing agents.
In the control group, incubation of rings in buffer solution
containing high concentrations of TG, LPC or glucose resulted
in the development of significant impairment of endothelium-
dependent relaxation, as evidenced by increased EC50 values
for ACh (Table 2; Fig. 2) or decreased maximal endothelium-
dependent relaxation in response to ACh (Fig. 3).
In the control group, following the incubation of rings in high-
glucose buffer solution, EC50 values for ACh increased from
39  8 to 81  14 nmol/L (P < 0.001). Pretreatment of rats
with mildronate or L-carnitine did not result in the development
of protection against the development of impaired endothelial
function following incubation of rings in high-glucose solution
(Fig. 2). The EC50 values for ACh before and after incubation of
rings in high-glucose solution were 35  4–64  11 nmol/L,
Table 1 Plasma concentrations of L-carnitine, c-butyrobetaine and mildro-








Control 48  3 0.6  0.1† –
Mildronate 22  2*† 6.1  0.9*† 35  9†
L-Carnitine 64  3*† 0.9  0.1*† –
Mildronate + L-carnitine 50  1 16.0  3.9* 7  1
Data are the mean  SEM (n = 5–6 rats). *P < 0.05 compared with
the control group; †P < 0.05 compared with the combination group (one-
way ANOVA followed by Tukey’s multiple comparison test as a post-test;
six multiple comparisons).
Administration of mildronate decreased L-carnitine concentration in
plasma, whereas administration of L-carnitine increased the amount of
L-carnitine in plasma. In addition, treatment of rats with mildronate and
the combination of mildronate and L-carnitine increased plasma concentra-
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Fig. 2 Effects of the administration of (a) vehicle (water), (b) mildronate, (c) L-carnitine and (d) a combination of mildronate and L-carnitine on the
development of endothelial dysfunction induced by a high glucose concentration (44 mmol/L) in buffer solution. (□), responses to acetylcholine (ACh)
before incubation with high glucose; (■), responses to ACh after incubation with high glucose. Incubation of aortic rings in buffer solution with high
glucose induced impairment of endothelial function. Treatment of rats with mildronate or L-carnitine did not attenuate the development of endothelial
dysfunction, whereas administration of the combination did. Data are the mean  SEM (n = 5–6). *P < 0.05 compared with the corresponding response
curve before incubation with 44 mmol/L glucose (repeated-measures ANOVA followed by Bonferroni’s multiple comparison test as post-test; four multiple
comparisons).
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respectively (P < 0.01), in the mildronate group and 32 
2–60  8 nmol/L, respectively (P < 0.05), in the L-carnitine
group. However, there was no significant impairment of endothe-
lial function in aortic rings from rats treated with the combination
of mildronate and L-carnitine, with EC50 values for ACh before
and after incubation with high-glucose solution being 30  8
and 51  9 nmol/L, respectively (Fig. 2).
Incubation of aortic rings with mannitol for 3 h did not induce
any changes in responses to ACh, with EC50 values before and
after mannitol incubation being 44  5 and 49  5 nmol/L
ACh, respectively (n = 6).
The other two endothelial dysfunction-inducing agents
impaired endothelial function in aortic rings from rats in the con-
trol group. The most prominent impairment of endothelial func-
tion was observed after incubation of aortic rings in the presence
of 5 lmol/L LPC. In this experiment, endothelial-dependent
relaxation did not reach 50% of the phenylephrine-induced sub-
maximal contraction in a subset of aortic rings. Therefore, we did
not calculate EC50 values, but chose to compare endothelial func-
tion by comparing Emax values between groups, as reported
previously by other researchers using this experimental model.12
As indicated in Fig. 3 and Table 2, none of the pretreatments
attenuated the development of endothelial dysfunction induced by
TG or LPC.
Incubation of aortic rings with high glucose concentrations did
not alter SNP-induced relaxation, with EC50 values before and
after incubation being 6.2  1.4 and 4.6  0.8 nmol/L SNP,
respectively (n = 6). However, incubation of aortic rings in buf-
fer containing 10 mmol/L TG reduced SNP-induced relaxations,
with EC50 values before and after incubation with TG being
8.3  0.5 and 43.5  10.9 nmol/L SNP, respectively (n = 7;
P = 0.005). In addition, incubation of aortic rings with LPC for
30 min slightly but significantly decreased the Emax from
103  1 to 94  2% (n = 6; P = 0.03).
DISCUSSION
In the present study we investigated whether changes in aortic
tissue levels of L-carnitine and GBB have vasoprotective effects
in experimental models of endothelial dysfunction. In our proto-
cols, endothelial dysfunction was induced by incubation of aortic
rings in buffer solutions containing LPC, TG or high glucose.
The results showed that administration of the combination of
L-carnitine and mildronate, which elevated vascular tissue levels
of GBB and had no effect on L-carnitine levels, attenuated the
development of endothelial dysfunction induced by high glucose.
Chromatographic analysis of aortic tissue extracts and plasma
samples revealed that L-carnitine treatment elevated L-carnitine
levels, but that administration of mildronate simultaneously
decreased L-carnitine levels and increased GBB levels. Similar
changes in vascular tissue and plasma levels of GBB and L-carni-
tine have been reported previously.8,9 However, herein we
showed, for the first time, that simultaneous administration of
L-carnitine and mildronate increases vascular tissue levels of
GBB without affecting vascular tissue levels of L-carnitine. This
approach allowed us to study the direct effect of elevated GBB
levels in vascular tissues on the impairment of endothelial func-
tion while excluding the effects induced by changes in L-carnitine
levels. In previous studies we found that simultaneous administra-
tion of L-carnitine and mildronate caused a more pronounced
increase in plasma GBB concentrations than treatment with
mildronate alone.2,9 However, in both the myocardium2 and vas-
cular tissues (present study), treatment with mildronate or the
combination of L-carnitine and mildronate induced similar
increased in tissue levels of GBB. Because GBB can be synthes-
ised in various tissues,19 we propose that the administration of
100 mg/kg mildronate inhibited GBB dioxygenase4 and increased
the tissue content of GBB to the highest pharmacologically
attainable level. Moreover, similar conclusions can be drawn
from the study in which experimental rats were treated with
different doses of mildronate (100, 200 and 400 mg/kg), although
the increase in the GBB content in heart tissues was similar
across all treatment groups.20 The differences in GBB plasma
levels between groups receiving mildronate and the combination
of mildronate plus L-carnitine could be due to the intestinal
metabolism of L-carnitine to GBB, which can then be absorbed




















Fig. 3 Effect of administration of vehicle (water), mildronate, L-carnitine
or their combination on the maximal relaxation (Emax) response induced
by acetylcholine before (■) and after (□) incubation of aortic rings with
5 lmol/L lysophosphatidylcholine (LPC). Incubation of aortic rings with
5 lmol/L LPC significantly decreased Emax in the control group. None of
the treatments used in the study attenuated the impairment of endothelial
function. Data are the mean  SEM (n = 6 rats). *P < 0.05 compared
with the corresponding control (paired t-test).
Table 2 EC50 values for acetylcholine-induced relaxation in aortic rings
before and after incubation in buffer solution containing 10 mmol/L tri-
glyceride
EC50 (nmol/L ACh)
Before TG After TG
Control 35  4 294  52*
Mildronate 30  2 370  103*
L-carnitine 35  5 343  61*
Mildronate + L-carnitine 52  10 290  92*
ACh, acetylcholine.
Data are the mean  SEM (n = 6 rats). *P < 0.05 compared with the
corresponding response curve before incubation with 10 mmol/L triglyc-
eride (TG; repeated-measures ANOVA followed by Bonferroni’s multiple
comparison test as post-test; four multiple comparisons).
Incubation of aortic rings in buffer solution with 10 mmol/L TG
induced impairment of endothelial function. None of the pretreatments
attenuated the development of endothelial dysfunction.
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reached and studied the effects of the highest pharmacologically
attainable vascular tissue levels of GBB in our experimental
protocol.
Until now not much experimental evidence concerning the vas-
cular effects of GBB has been reported, although elevation of
vascular levels of GBB, together with reduced amounts of L-car-
nitine, has been connected with the anti-atherosclerotic effect of
mildronate.8 However, in several experimental protocols, the
methyl ester of GBB has been demonstrated to have ACh-like
activity on the vascular endothelium.22
Previous studies have shown that the administration of mildro-
nate induced vasoprotective effects in experimental models of ath-
erosclerosis8 and Type 2 diabetes.3 Although treatment with
mildronate induced expected changes in vascular tissue levels of
GBB and L-carnitine in the present study, we did not observe atten-
uation of the endothelial dysfunction induced by any of the agents
that are involved in the development of endothelial dysfunction in
atherosclerosis, diabetes and metabolic syndrome. Thus, we think
that the vasoprotective effects of mildronate may be the result of a
different molecular mechanism or that mildronate treatment in dis-
eased organisms induces different changes than in healthy ones.
Treatment with L-carnitine has been demonstrated to attenuate
the development of endothelial dysfunction in different experimen-
tal disease models.23–25 Nevertheless, none of these studies has
measured the amount of L-carnitine in vascular tissues or investi-
gated whether the vasoprotective effects of L-carnitine were
induced by a direct action of L-carnitine on vascular tissues or
whether it is a secondary effect of carnitine supplementation. In our
experimental protocol, administration of 100 mg/kg L-carnitine ele-
vated the L-carnitine content in vascular tissue by 36%. However,
we did not observe attenuation of the impairment of endothelial
function in any of the experimental protocols that we used. This
may be explained by the use of a lower dose of L-carnitine com-
pared with that used in other studies that have shown vasoprotec-
tive effects of L-carnitine using two- to sixfold higher doses.23–25
The administration of a combination of mildronate and L-carni-
tine attenuated the development of endothelial dysfunction
induced by high glucose and, at the same time, elevated the GBB
content and had no effect on vascular tissue levels of L-carnitine.
We suppose that the vasoprotective effect in this experimental
group is due to both elevated GBB levels and unchanged L-carni-
tine levels. If it were a GBB-dependent effect, we would have
also observed vasoprotective effects in the mildronate group. If
the effect had been L-carnitine dependent, we would have
observed vasoprotective effects in the L-carnitine group. How-
ever, we did not observe an attenuation of the development of
endothelial dysfunction in either of these two groups.
It has been proposed that the endothelial dysfunction induced
by high glucose is mediated through the activation of protein
kinase C (PKC).26 Activation of PKC induces alterations in the
prostanoid profile and the generation of reactive oxygen species27
that could lead to a reduction in nitric oxide (NO) levels and loss
of endothelium-dependent vasodilatation. Several studies have
demonstrated that NO availability can be increased or that the
development of endothelial dysfunction induced by high glucose
can be attenuated by inhibition of PKC,27 increasing heme
oxygenase-1 activity28 or by superoxide anion scavenging
molecules.27 Until now there is no experimental evidence that
GBB interacts with any of the previously mentioned proteins.
However, it has been shown that direct administration of GBB in
rat isolated heart decreases the development of mechanical
dysfunction induced by infusion of hydrogen peroxide7; thus, the
vasoprotective effect of GBB could be due to a reduction in oxi-
dative stress in the vascular wall.
Our results demonstrate that increasing GBB levels while
preserving L-carnitine content in vascular tissues attenuates the
development of endothelial dysfunction induced by high glucose.
This approach could represent a method for the attenuation of the
development of endothelial dysfunction in cases of hyperglyca-
emia, including diabetes.
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